Novalpina Capital takes majority stake in Laboratoire X.O
Context
Novalpina Capital made its first French investment by acquiring a controlling stake in Laboratoire X.O. The deal values the company at over EUR300M, supported by a unitranche debt facility from Ares Management. Novalpina has also reserved EUR100M for future acquisitions. The objective is to triple revenue within five years by acquiring more drug portfolios and expanding the group's international footprint beyond France and Francophone Africa.
Laboratoire X.O, which reported an EBITDA margin of [members only] in 2019, is valued in this transaction at an EV/EBITDA multiple of [members only].
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in 2015, Laboratoire X.O is a specialty pharmaceutical company focused on acquiring and revitalizing mature drug brands (Legacy Brands) from "Big Pharma." It operates an asset-light model, outsourcing production while managing 21 Market Authorizations (MA). Its portfolio includes prescription drugs and a growing Over-The-Counter (OTC) division, with key brands like Prexidine (mouthwash).
Ent. Value
[members only]
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Laboratoire X.O
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2022 | STANLEY CAPITAL PARTNERS | LABORATOIRE X.O | FRANCE | Generics / Labs |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 01/2021 | ARDIAN / BNP PARIBAS DEVELOPPEMENT | PROTEOR | FRANCE | Implants & Prosthetics |
| 01/2021 | MONTAGU PRIVATE EQUITY | IMV TECHNOLOGIES | FRANCE | R&D Biotech |
| 10/2020 | SULZER | HASELMEIER | SWITZERLAND | Medical Consumables |
| 10/2020 | ARDIAN | H2 PHARMA | FRANCE | CDMO |
| 09/2020 | NESTLE | IM HEALTHSCIENCE | UNITED STATES | Nutrition & Dietary Supplements |
| 09/2020 | PATRICIA INDUSTRIES | ADVANCED INSTRUMENTS | UNITED STATES | Diagnostic Equipment |
| 09/2020 | EQT PARTNERS | SCHÜLKE | GERMANY | Medical Consumables |
| 09/2020 | PERMIRA | NEURAXPHARM | GERMANY | Generics / Labs |
| 06/2020 | AVISTA CAPITAL PARTNERS | VISION HEALTHCARE | BELGIUM | Nutrition & Dietary Supplements |
| 04/2020 | ROYAL DSM | GLYCOM | DENMARK | Nutrition & Dietary Supplements |
REFERENCES
Revenue range: REV €25–50M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Laboratoire X.O by Novalpina Capital are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
FAQ
What transaction does this page cover?
What was Laboratoire X.O’s revenue at the time of the deal?
What sources support the information on this transaction?
What is mynth?